Security
Disc Medicine, Inc. Common Stock · IRON
IRONNASDAQCommon stockCurrentCIK 1816736Updated Oct 27, 2026
Name history
Gemini Therapeutics, Inc. /DE · through Dec 28, 2022FS Development Corp. · through Feb 8, 2021
IRON price & chart
Loading TradingView…
NASDAQ:IRON on TradingView ↗About the company
Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
In the news
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights ↗
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON ↗
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON ↗
Recent filings
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Other Events
Items 1.01, 2.02, 8.01, 9.01
4 filing
424B5 filing
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 630,456,000Source | 495,145,000Source | 735,071,000Source | 665,061,000Source | 510,217,000Source | 750,213,000Source | 709,266,000Source | 354,182,000Source | 806,879,000Source | 496,773,000Source | 367,996,000Source | 200,205,000Source |
| Property, Plant and Equipment, NetUSD | 1,228,000Source | 79,000Source | 980,000Source | 1,289,000Source | 98,000Source | 1,070,000Source | 1,370,000Source | 211,000Source | 1,159,000Source | 751,000Source | 170,000Source | 168,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 140,664,000Source | 192,638,000Source | 98,676,000Source | 127,337,000Source | 280,663,000Source | 88,913,000Source | 122,675,000Source | 342,615,000Source | 91,145,000Source | 192,434,000Source | 360,382,000Source | 194,611,000Source |
| Assets, CurrentUSD | 627,168,000Source | 493,152,000Source | 732,761,000Source | 661,592,000Source | 508,241,000Source | 747,455,000Source | 705,600,000Source | 351,948,000Source | 803,898,000Source | 493,615,000Source | 365,662,000Source | 198,491,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,248,000Source | 5,789,000Source | 15,015,000Source | 11,619,000Source | — | 17,297,000Source | 10,938,000Source | — | 12,746,000Source | 3,734,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 1,220,000Source | 1,678,000Source | 834,000Source | 1,340,000Source | 1,642,000Source | 967,000Source | 1,457,000Source | 1,788,000Source | 1,096,000Source | 1,569,000Source | 1,930,000Source | 1,430,000Source |
| Other Assets, NoncurrentUSD | 840,000Source | 236,000Source | 496,000Source | 840,000Source | 236,000Source | 721,000Source | 839,000Source | 235,000Source | 726,000Source | 838,000Source | 234,000Source | 116,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 57,065,000Source | 27,185,000Source | 90,907,000Source | 50,896,000Source | 21,388,000Source | 61,784,000Source | 48,904,000Source | 16,111,000Source | 67,053,000Source | 53,186,000Source | 22,875,000Source | 23,605,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 4,000Source | 3,000Source | 3,000Source | 4,000Source | 3,000Source | 2,000Source | 4,000Source | 3,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 1,022,324,000Source | 735,761,000Source | 1,278,990,000Source | 1,001,223,000Source | 730,832,000Source | 1,262,686,000Source | 991,911,000Source | 553,663,000Source | 1,249,043,000Source | 741,297,000Source | 533,764,000Source | 288,814,000Source |
| Retained Earnings (Accumulated Deficit)USD | -449,655,000Source | -268,545,000Source | -633,222,000Source | -387,334,000Source | -241,946,000Source | -573,690,000Source | -332,087,000Source | -215,594,000Source | -510,186,000Source | -298,002,000Source | -188,645,000Source | -112,216,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 718,000Source | 741,000Source | -1,608,000Source | 273,000Source | -60,000Source | -571,000Source | 535,000Source | — | 965,000Source | 289,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 573,391,000Source | 467,960,000Source | 644,164,000Source | 614,165,000Source | 488,829,000Source | 688,429,000Source | 660,362,000Source | 338,071,000Source | 739,826,000Source | 443,587,000Source | 345,121,000Source | 176,600,000Source |
| Liabilities and EquityUSD | 630,456,000Source | 495,145,000Source | 735,071,000Source | 665,061,000Source | 510,217,000Source | 750,213,000Source | 709,266,000Source | 354,182,000Source | 806,879,000Source | 496,773,000Source | 367,996,000Source | 200,205,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 26,744,000Source | 25,473,000Source | 30,360,000Source | 20,606,000Source | 20,310,000Source | 31,142,000Source | 18,741,000Source | 14,852,000Source | 36,641,000Source | 23,316,000Source | 21,439,000Source | 22,578,000Source |
| Operating Lease, Liability, CurrentUSD | 656,000Source | 76,000Source | 315,000Source | 632,000Source | 759,000Source | 419,000Source | 479,000Source | 767,000Source | 611,000Source | 130,000Source | 665,000Source | 307,000Source |
| Accounts Payable, CurrentUSD | 7,268,000Source | 3,553,000Source | 6,840,000Source | 6,350,000Source | 4,749,000Source | 11,759,000Source | 6,703,000Source | 5,269,000Source | 9,018,000Source | 7,948,000Source | 12,629,000Source | 16,162,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,373,000Source | 1,712,000Source | 1,207,000Source | 1,553,000Source | 1,078,000Source | 1,277,000Source | 1,634,000Source | 1,259,000Source | 1,253,000Source | 1,548,000Source | 1,436,000Source | 1,027,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 11,115,000Source | 5,512,000Source | 8,881,000Source | 6,161,000Source | 4,451,000Source | 6,827,000Source | 4,138,000Source | 8,816,000Source | 15,561,000Source | 8,097,000Source | 8,145,000Source | 6,109,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 615,900,000Source | 487,400,000Source | 717,700,000Source | 650,000,000Source | 500,900,000Source | 730,200,000Source | 694,700,000Source | — | 791,200,000Source | 489,900,000Source | — | — |
| Long-term DebtUSD | 28,948,000Source | — | 59,340,000Source | 28,737,000Source | — | 29,365,000Source | 28,529,000Source | — | 29,159,000Source | 28,322,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -76,429,000Source | -46,827,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 89,000Source | 20,000Source | 281,000Source | 156,000Source | 100,000Source | 89,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 11,946,000Source | 6,363,000Source | 34,340,000Source | 16,815,000Source | 5,530,000Source | 2,089,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,741,000Source | -1,277,000Source | 1,070,000Source | -4,681,000Source | -3,741,000Source | 526,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -62,236,000Source | -41,376,000Source | -180,393,000Source | -93,926,000Source | -73,462,000Source | -42,252,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 58,307,000Source | -272,633,000Source | -394,299,000Source | -292,332,000Source | -89,000Source | -151,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 851,000Source | 933,000Source | 505,000Source | 89,000Source | 151,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,697,000Source | 244,251,000Source | 473,407,000Source | 218,314,000Source | 239,379,000Source | 148,978,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,232,000Source | -69,758,000Source | -101,285,000Source | -167,944,000Source | 165,828,000Source | 106,575,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 140,904,000Source | 192,874,000Source | 98,918,000Source | 127,577,000Source | 89,155,000Source | 122,914,000Source | 91,387,000Source | 192,672,000Source | 360,616,000Source | 194,788,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 640,000Source | 698,000Source | 2,795,000Source | 198,000Source | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 349,000Source | 299,000Source | 112,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 9,514,000Source | 4,332,000Source | 13,948,000Source | 8,420,000Source | 11,946,000Source | 6,363,000Source | 34,340,000Source | 16,815,000Source | 5,530,000Source | 2,089,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 615,900,000Source | 487,400,000Source | 717,700,000Source | 650,000,000Source | 730,200,000Source | 694,700,000Source | 791,200,000Source | 489,900,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 200,000Source | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -61,000Source |
| General and Administrative ExpenseUSD | — | — | — | 8,171,000Source | — | — | — | — | — | — | 21,861,000Source | 14,038,000Source |
| Income Tax Expense (Benefit)USD | — | — | 102,000Source | 114,000Source | 69,000Source | 52,000Source | 51,000Source | 119,000Source | 361,000Source | 355,000Source | 99,000Source | — |
| InterestExpenseNonoperatingUSD | — | — | 917,000Source | 0Source | 908,000Source | 910,000Source | 844,000Source | 897,000Source | 3,607,000Source | 572,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -62,321,000Source | -26,599,000Source | -59,532,000Source | -55,247,000Source | -63,504,000Source | -34,085,000Source | -212,184,000Source | -109,357,000Source | -76,429,000Source | -46,827,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -26,599,000Source | — | — | — | — | — | — | -76,429,000Source | -46,827,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,477,000Source | 6,371,000Source | 5,612,000Source | 6,215,000Source | 6,071,000Source | 5,980,000Source | 24,199,000Source | 20,718,000Source | 14,795,000Source | 648,000Source |
| Operating ExpensesUSD | — | — | 67,696,000Source | 32,856,000Source | 65,075,000Source | 61,410,000Source | 69,524,000Source | 39,946,000Source | 236,022,000Source | 129,720,000Source | 91,125,000Source | 47,475,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -18,000Source | 9,000Source | -12,000Source | 68,000Source | 22,000Source | -3,000Source | 45,000Source | -2,000Source | -2,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 53,500,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 28,988,000Source | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 152,069,000Source | 75,468,000Source | 456,219,000Source | 94,800,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,010,000Source | 575,000Source | 8,641,000Source | 2,976,000Source | 2,722,000Source | 219,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 17,362,000Source | 8,171,000Source | 18,142,000Source | 15,091,000Source | 23,620,000Source | 12,183,000Source | 65,382,000Source | 33,049,000Source | — | — |
| Operating Income (Loss)USD | — | — | -67,696,000Source | -32,856,000Source | -65,075,000Source | -61,410,000Source | -69,524,000Source | -39,946,000Source | -236,022,000Source | -129,720,000Source | -91,125,000Source | -47,475,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -18,000Source | 9,000Source | -12,000Source | 68,000Source | 22,000Source | -3,000Source | 45,000Source | -2,000Source | -2,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -62,219,000Source | -26,485,000Source | -59,463,000Source | -55,195,000Source | -63,453,000Source | -33,966,000Source | -211,823,000Source | -109,002,000Source | -76,330,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 102,000Source | 114,000Source | 69,000Source | 52,000Source | 51,000Source | 119,000Source | 361,000Source | 355,000Source | 99,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -62,321,000Source | -26,599,000Source | -59,532,000Source | -55,247,000Source | -63,504,000Source | -34,085,000Source | -212,184,000Source | -109,357,000Source | -76,429,000Source | -46,827,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.77Source | -0.89Source | -1.54Source | -1.58Source | -1.65Source | -1.02Source | -6.01Source | -3.96Source | -3.42Source | -45.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.77Source | -0.89Source | -1.54Source | -1.58Source | -1.65Source | -1.02Source | -6.01Source | -3.96Source | -3.42Source | -45.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 35,178,691Source | 29,935,551Source | 38,685,565Source | 35,024,592Source | 38,491,433Source | 33,324,745Source | 35,295,663Source | 27,606,022Source | 22,315,877Source | 1,039,490Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 35,178,691Source | 29,935,551Source | 38,685,565Source | 35,024,592Source | 38,491,433Source | 33,324,745Source | 35,295,663Source | 27,606,022Source | 22,315,877Source | 1,039,490Source |
| Interest Expense (non-operating)USD | — | — | 917,000Source | 0Source | 908,000Source | 910,000Source | 844,000Source | 897,000Source | 3,607,000Source | 572,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 361,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 8,171,000Source | — | — | — | — | — | — | 21,861,000Source | 14,038,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -212,152,000Source | — | — | — |
| Interest Income, OtherUSD | — | — | 6,412,000Source | 6,362,000Source | 6,532,000Source | 7,057,000Source | 6,893,000Source | 6,880,000Source | 27,761,000Source | 21,292,000Source | 14,797,000Source | 709,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -26,599,000Source | — | — | — | — | — | — | -76,429,000Source | -46,827,000Source |
| Nonoperating Income (Expense)USD | — | — | 5,477,000Source | 6,371,000Source | 5,612,000Source | 6,215,000Source | 6,071,000Source | 5,980,000Source | 24,199,000Source | 20,718,000Source | 14,795,000Source | 648,000Source |
| Operating ExpensesUSD | — | — | 67,696,000Source | 32,856,000Source | 65,075,000Source | 61,410,000Source | 69,524,000Source | 39,946,000Source | 236,022,000Source | 129,720,000Source | 91,125,000Source | 47,475,000Source |
| Research and Development ExpenseUSD | — | — | 50,334,000Source | 24,685,000Source | 46,933,000Source | 46,319,000Source | 45,904,000Source | 27,763,000Source | 170,640,000Source | 96,671,000Source | 69,264,000Source | 33,437,000Source |
Filing attachments
d457786dex991.htm · 8-K · 2026-10-22
Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) - Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten public offering of $350 million of sh…
Read attachment ↗d457786dex992.htm · 8-K · 2026-10-22
Exhibit 99.2 Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock October 20, 2026 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) - Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. D…
Read attachment ↗d156263dex991.htm · 8-K · 2026-10-19
Exhibit 99.1 Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and increased total time in light ────────────────────────────────────…
Read attachment ↗d156263dex992.htm · 8-K · 2026-10-19
APOLLO Topline Results October 19, 2026 Exhibit 99.2 Disclaimer and FLS This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectations with respect to its preclinical studies, clinical trials and research and development programs, in particular with respect to bitopertin, selcodebart (DISC-0974) and DISC-3405, and any developments or res…
Read attachment ↗iron-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting • Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients • DISC-3405 is the first monoclonal antibody targeting TMPRSS6 that has d…
Read attachment ↗iron-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 • Launched Expanded Access Program (EAP) for bitopertin for eligible erythropoietic protoporphyria (EPP) patients • Presented positive clinical data updates fr…
Read attachment ↗